Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Capital Leases (2024 - 2025)

Humacyte has reported Capital Leases over the past 2 years, most recently at $27.0 million for Q4 2025.

  • Quarterly results put Capital Leases at $27.0 million for Q4 2025, up 98.05% from a year ago — trailing twelve months through Dec 2025 was $27.0 million (up 98.05% YoY), and the annual figure for FY2025 was $27.0 million, up 98.05%.
  • Capital Leases for Q4 2025 was $27.0 million at Humacyte, down from $27.2 million in the prior quarter.
  • Over the last five years, Capital Leases for HUMA hit a ceiling of $27.2 million in Q3 2025 and a floor of $12.0 million in Q2 2025.